RESUMO
<p><b>OBJECTIVE</b>To explore the predictors of axillary nodal metastass in patients with breast cancer.</p><p><b>METHODS</b>A retrospective study was performed using the clinicopathological data of breast cancer cases diagnosed and treated in our Hospital between Dec 2006 and Nov 2008. Logistic regression analysis was used to determine the predictors of axillary node positivity.</p><p><b>RESULTS</b>The total number of patients was 1133. 69.5% of them (787) had complete clinical and pathological data. The median age was 49 years old (range 20-85). The average number of lymph nodes removed was 14.6 per person. The average number of involved nodes was 3.5 per person. Increasing tumor size was associated with increased risk of lymph node metastases. Assessed by multivariate analysis, the tumor size, age, ER status, and pathological type were significantly associated with node metastasis.</p><p><b>CONCLUSIONS</b>Axillary nodal metastases are significantly affected by the tumor size, ER status, age, and pathological type in breast cancer patients.</p>
Assuntos
Adulto , Idoso , Idoso de 80 Anos ou mais , Feminino , Humanos , Pessoa de Meia-Idade , Adulto Jovem , Axila , Neoplasias da Mama , Metabolismo , Patologia , Cirurgia Geral , Carcinoma Ductal de Mama , Metabolismo , Patologia , Cirurgia Geral , Carcinoma Intraductal não Infiltrante , Metabolismo , Patologia , Cirurgia Geral , Carcinoma Lobular , Metabolismo , Patologia , Cirurgia Geral , Modelos Logísticos , Excisão de Linfonodo , Linfonodos , Patologia , Cirurgia Geral , Metástase Linfática , Receptores de Estrogênio , Metabolismo , Estudos Retrospectivos , Carga TumoralRESUMO
Objective To determine the efficacy and tolerability of docetaxel plus capecitabine as first-line treatment for breast cancer with liver metastases(BCLM).Methods Forty-two patients with BCLM received oral capecitabine 1900 mg/m~2/d(950 mg/m~2 twice daily)on days 1 through 14 and intravenous infu- sion of Docetaxel at 75 mg/m~2 on day 1 of each 21-day treatment cycle.Patients were evaluated for the re- sponse after two cycles.Results Among these 42 patients,the overall response rate was 54.76% with 4 CR, 19 PR, 9 SD and 6 PD.The clinical benefit rate was 64.28% and the median overall survival time was 17.5 months.The most common treatment-related adverse events were leukopenia(76.1%),neutropenia(71.4%), hand-foot syndrome(45.2%),nausea and vomiting(52.3%),which were mainly gradeⅠ～Ⅱ.Conclusion The combination of docetaxel plus capocitabine is a highly active and generally well-tolerated regimen for first-line treatment of BCLM.